Markets:

Overview

News

Currencies

International

Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

344.24 -3.82 (-1.10%)

Streaming Delayed Price Updated: 1:32 PM EDT, Jun 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment ↗

May 22, 2023

The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with

Via Benzinga

Why Shares of Krystal Biotech Are Rising Monday ↗

May 22, 2023

The company is moving quickly to market its newly approved therapy.

Via The Motley Fool

Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action

May 22, 2023

Via Investor Brand Network

Analyst Expectations for Krystal Biotech's Future ↗

May 22, 2023

Via Benzinga

FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder ↗

May 22, 2023

The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic

Via Benzinga

NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday ↗

May 22, 2023

Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday.

Via Benzinga

Expert Ratings for Krystal Biotech ↗

February 28, 2023

Via Benzinga

Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine ↗

December 15, 2022

Via Benzinga

2 Risky Stocks That Could Soar in 2023 ↗

December 06, 2022

These "exciting" companies aren't for everyone.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 ↗

April 18, 2023

Via Benzinga

Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday ↗

February 28, 2023

U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles ↗

November 17, 2022

Via Benzinga

Recap: Krystal Biotech Q3 Earnings ↗

November 07, 2022

Krystal Biotech (NASDAQ:KRYS) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗

February 28, 2023

Via Benzinga

Have A Look At William Blair's Top Biotech Picks For 2023 ↗

December 25, 2022

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

Via Benzinga

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond ↗

December 18, 2022

Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year.

Via InvestorPlace

SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International ↗

November 08, 2022

Goldman Sachs raised the price target on Mettler-Toledo International Inc. (NYSE: MTD) from $1,120 to $1,335. Goldman Sachs analyst Matthew Sykes upgraded the stock from Sell to Neutral. Mettler-Toledo...

Via Benzinga

Recap: Krystal Biotech Q4 Earnings ↗

February 28, 2022

Krystal Biotech (NASDAQ:KRYS) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25% ↗

November 08, 2022

SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review ↗

August 18, 2022

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with...

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study ↗

August 01, 2022

The United States Food and Drug Administration (FDA) has accepted Krystal Biotech’ (NASDAQ: KRYS) Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis...

Via Benzinga

Krystal Biotech Files To Seek Approval For Skin Disease Candidate ↗

June 22, 2022

Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of...

Via Benzinga

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗

April 14, 2022

On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.

Via Investor's Business Daily

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise ↗

January 18, 2022

Krystal Biotech Inc (NASDAQ:KRYS) shares have po...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.